Abstract
The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anti-cancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data we performed a structural activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasomal deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore using active site directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasomal DUBs, on recombinant kinases or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor. domains. Four of these families are cysteine proteases and one family consist of metalloproteases (3) . Cancer cells in particular are extremely sensitive to disruptions in the UPS, presumably due to the high rates of protein turnover. Even small fluctuations in UPS activity can trigger severe proteotoxic stress resulting in the accumulation of high-molecular weight ubiquitinated proteins, apoptosis and ultimately cell death (4, 5) . This dependency of cancer cells for a functioning UPS has been exploited by the recent development of UPS inhibitors. In particular the high-lighted the potential of targeting the UPS for cancer drug development (6, 7) .
We have previously identified the chalcone-derivative b-AP15 as a small molecule that inhibits the activity of the proteasomal deubiquitinases USP14 and UCHL5 (8) .
Exposure of cancer cells to b-AP15 results in the rapid accumulation of ubiquitinated proteins and an acute proteotoxic stress response without altering the proteolytic capacity of the 20S CP. The drug shows anti-neoplastic activity in a number of syngeneic and xenograft tumor models, including multiple myeloma at doses that were well tolerated (8, 9) . Importantly, b-AP15 induced cell death in multiple myeloma cells that had acquired resistance to bortezomib (9) raising the possibility of using proteasome DUB inhibitors in anti-cancer therapies to overcome acquired drug resistance. The structure of b-AP15 contains Michael acceptors that likely bind the cysteine residues in the active site of USP14 and UCHL5. This inhibitory effect of b-AP15 appears to be specific for proteasomal DUBs since it does not inhibit total DUB enzymatic activity in cell extracts. There is growing recognition of the potential of proteasome DUB inhibitors as an anti-cancer therapy with several small molecule inhibitors of proteasome DUB activity described. A chalcone-derivative (RA-9) with a similar structure to b-AP15 was recently described as an inhibitor of proteasomal DUB activities (10) . Furthermore, the curcumin analog AC17 was reported to inhibit proteasomal DUB activity as well as display in vivo antineoplastic activity on lung carcinoma xenografts (11) . Similar to b-AP15, both AC17 and RA-9 contain two α,β 0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8 9 0 shows limited solubility and stability in aqueous solution and requires high concentrations of Kolliphor EL in formulas for parenteral injections (8, 9) . In this report we have evaluated the structure-activity characteristics of b-AP15 in an attempt to optimize both anti-tumor activity and chemical properties. From our analysis the lead compound VXL1570 showed a similar target specificity and mechanism of action to b-AP15. Furthermore the improved solubility of VLX1570
allows for the use of excipients which are more suitable for clinical administration. 0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6 incubated at 37°C in 5% CO 2 . Cell viability was monitored using the FMCA assay (12) or using the MTT assay (13) .
Western blot analysis
Cell extract proteins were resolved by 3-8% proteasomes (50 nM) with DMSO, VLX1570 or b-AP15 (50 µM) for 10min at room temperature, followed by labeling with 1 µM HA-UbVS for 30 min at 37°C and by immunoblotting.
Caspase-3 enzyme activity
Caspase-3 activity was determined using Sensolyte Homogeneous Rh110
Caspase-3/7 Assay Kit (Eurogentec, Liege, Belgium). Briefly, different concentrations of VLX1570 were incubated with caspase 3 for 15 min at 37°C before the addition of Rh110 caspase 3/7 substrate, and then continuously measured on a fluorometric 
Bacterial reverse mutation assay
The potential to induce reversion mutations in the histidine operon was assayed in the Salmonella typhimurium tester strains TA98, TA100, and in Escherichia coli strain WP2 uvrA as described. Mutation test was carried out using the preincubation method (30 min, 37°C) with and without phenobarbital-5,6-benzoflavone induced rat liver metabolic (S9) activation. These experiments were performed by Accelera, Nerviano, Italy.
Pharmacokinetics
Approximately three days before dosing and while under anesthesia (an aqueous mixture of ketamine, xylazine and acepromazine, subcutaneously administered), male Sprague Dawley rats (6 weeks, supplied by Charles River Laboratories, Italia)
were surgically prepared for serial blood samples collection. The animals were fitted with a flexible 3F-polyurethane cannula (Biomedica Greto; method of sterilization:
ethylene oxide) implanted in the superior vena cava via the jugular vein. VLX1570
was administered in the vehicle as IV slow injection in a fixed time of 10 minutes via tail vein. The compound was dissolved in 50% PEG400/40% Tween-80/10%
Kolliphor EL and then diluted with saline. The drug was injected at a final dose of 5 mg/kg during 10 minutes. 
Computational docking
Initial docking for VLX1570 was performed using Glide (v. (14) . Our docking methodology has been described previously (16) (17) (18) , and the scoring function utilized has been described (19) . Briefly, in order to generate the grids for docking, molecular refracting molecules were removed from the USP14 or UCHL5 crystal structure (PDB Codes: showed somewhat lower potency than VLX1570, which contained an acrylamide at suggesting that VLX1570 and metabolized products is non-mutagenic. The significantly increased potency of VLX1570 compared to b-AP15 and the lower requirement for Kolliphor EL led us to select this compound for further studies.
Predicted interaction of UCHL5 with VLX1570 via in silico docking
The catalytic cysteine residue 88 of UCHL5 may be attacked by VLX1570 via a
Michael's addition reaction. The compound fits deep into a wedge-like crevice inside UCHL5 that includes the following residues within 4 Å of the small molecule: Leu10, Trp58, Gln82, Asn85, Cys88 (covalent linkage), Ala162, Phe163, His164, Phe165 
Predicted interaction of USP14 with VLX1570 via in silico docking
USP14 is predicted to bind the VLX1570 inhibitor via a Michael's addition reaction at the thiol of residue Cys114 with the electrophilic β-carbon of the small molecule ( Figure 2C, D) . The crevice for USP14 is deeper and includes the following residues within 4 Å of the small molecule VLX1570: Asn109, Asn112, Cys114, Tyr115, Gln197, Gln198, Asp199, Ser431, Ser432, Ser433, Gly434, His435, Tyr436 and Lys454. The VLX1570 drug has a binding mode that would block access to the Cterminus of ubiquitin for binding with USP14, as visible in X-ray structure 2AYO7 and our model ( Figure 2C; Supplementary Figure 5 ). An electrostatic colored surface rendering for UCHL5 shows the fit of the top XP docked ligands prior to covalent bond formation. As with UCHL5, Asn and Gln interactions stabilize the nitrosubstituted phenyl rings, while the His435 is not facing the β-carbon in this insertion pose for VLX1570. VLX1570 potentially could insert in a 180° rotated orientation, such that VLX1570 faces the His435 similar to UCHL5, but the most optimal pose Figure 6) .
Thiol reactivity of the electrophilic β β β β-carbons of VLX1570
The α, β-unsaturated carbonyls of this series of compounds is expected to interact with the thiolates of active site cysteines in DUBs by Michael addition (26). This reactivity suggests that thiol-containing compounds such as dithiotreitol (DTT) would impair the cytotoxic activity of the compounds by Michael addition, as shown for similar compounds (27, 28). We indeed found that addition of DTT to the culture medium reduced VLX1570 cytotoxicity (Figure 3 ). However, DTT had to be added in large molar excess to alleviate the cytotoxity of the drug, showing that complex formation between VLX1570 and DTT is strongly shifted towards free molecules.
Analysis of metabolism and pharmacokinetics
The metabolic pattern of VLX1570 was investigated in human cryopreserved hepatocytes. The results suggested extensive metabolism or cellular uptake of the compound with only small amounts of parental drug detected after 2 hours incubation. A total of 20 different metabolites were formed of which the Phase I metabolism included several hydrogenation (+2H) and hydroxylation reactions, and defluorination of the side aryls was also observed ( Figure 4A , Table 1 ). Drug conjugates included those with S-glutathione (GSH), S-cysteinyl glycine and Scysteine. Many of these reactions occurred in conjunction with defluorination, Surprisingly, quite few metabolites involving the α, β-unsaturated carbonyls were detected, suggesting that these elements might not be highly reactive, or that the conjugates formed are reversible. VLX1570 showed a rapid half-life in rat plasma after injection ( Figure 4B ) with kinetics similar to that observed with the hit compound b-AP15 (24). A C max of 30.8 + 1.3 ng/mL was observed.
VLX1570 induces a similar cellular response as b-AP15
Blocking of proteasome function is known to induce the expression of a cellular chaperone response, induction of ER stress and oxidative stress (8, (29) (30) (31) (32) .
Microarray analysis showed that VLX1570 induces chaperone expression (HSPA6, HSPA1L, HSPA4L), the oxidative stress marker HMOX1 (known to be induced by bortezomib (33)), and the ER stress-associated marker DDIT3/CHOP in MCF7 cancer cells (Supplementary Table 3 ). The gene expression profile was similar to that induced by b-AP15 (Supplementary Table 3 , Supplementary Figure 7) . We also examined the response to VLX1571, an analogue of VLX1570 where the acrylamide moiety on the azepane ring is substituted to an acetamide. The response to this compound was very similar to that of b-AP15 and VLX1570 (Supplementary Table 3 , Supplementary Figure 7 ).
VLX1570 is a competitive inhibitor of proteasomal DUB activity
Inhibition of 19S deubiquitinase activity was assayed in vitro using the substrate UbRhodamine. VLX1570 showed a similar IC 50 (6.4 + 2.2 µM) to b-AP15 (6.5 + 2.9 µM) in this assay. VLX1570 was somewhat more potent than b-AP15 when Ub-AMC We examined the extent of polyubiquitin accumulation in HCT116 cells exposed to VLX1570 and compared it with other UPS inhibitors ( Figure 5C ). VLX1570 and b-AP15 induced similar levels of polyubiquitin; these levels were higher compared to those found in cells exposed to bortezomib. The average molecular weights of polyubiquitinated proteins were similar in cells exposed to b-AP15 and VLX1570, and higher compared to cells exposed to bortezomib ( Figure 5C ). This observation is consistent with a mechanism of DUB inhibition, as previously discussed (8) . The hours, but not after 18 hours ( Figure 5C ). This compound was strongly cytotoxic with few cells remaining at later time-points.
VLX1570 shows specificity to proteasomal DUB activity
The Michael acceptor reactivity of b-AP15 and VLX1570 may be expected to lead to broad inhibitory activity towards cysteine proteases. However, we previously found that whereas b-AP15 inhibited proteasomal cysteine DUB activity without altering the activities of non-proteasomal associated cytosolic DUBs (8) . To further confirm these findings we performed a deubiquitinase profiling experiment using recombinant enzymes treated with VLX1570 (experiment performed by Ubiquigent Ltd, Dundee) ( Figure 6A ). Some inhibition of USP5 (~50%) was observed at a VLX1570 concentration of 20 µM, however, this appeared to be the exception since the activity of most DUBs tested was not significantly inhibited.
We also examined whether VLX1570 inhibits an unrelated cysteine protease, caspase-3. We did not, however, detect inhibition of caspase-3 at a concentration of 40 µM VLX1570 ( Figure 6B ). Finally, in order to further characterize the specificity and potential general reactivity of VLX1570, we determined the ability of the drug to inhibit a panel of kinases in vitro ( Figure 6C) . A kinase panel (211 separate enzymes) was tested for inhibition at a drug concentration of 10 µM, a standard concentration in kinase profiling experiments. Only one single kinase in the total panel was inhibited by > 50% (Cdk4), with the median level of inhibition being at 4% Figure 6C ).
The DUB inhibitor WP1130 contains an α, β-unsaturated carbonyl group and has been shown to inhibit USP14 and UCHL5, but also USP9x and USP5 (28). A decline in the levels of the antiapoptotic protein MCL-1 in cells exposed to WP1130 was reported (28), presumably due to loss of deubiquitination of MCL-1 by USP9x (35) .
Decreased levels of MCL-1 were indeed observed following exposure of MelJuSo cells to WP1130, whereas this effect was not observed in HCT116 cells (Figure 7) .
Interestingly, however, MCL-1 levels increased when these two cell lines were exposed to b-AP15/VLX1570 (Figure 7 ). These findings are consistent with the finding that VLX1570 does not inhibit USP9x, and show that different DUB inhibitors containing α, β-unsaturated carbonyl groups, but are otherwise chemically unrelated, may elicit distinct biological effects. 
Discussion
Proteasome inhibition has been established as a therapeutic treatment for multiple myeloma. We have previously shown that the proteasome DUB inhibitor b-AP15 displayed anti-tumor activity on multiple myeloma cells both in vitro and in vivo (9) .
Building on our previous hit compound, we performed a medicinal chemistry optimization of b-AP15 and found that compounds containing a central azepane ring were more potent than piperidine-based compounds. One of our primary motivations in performing this study was to obtain a lead compound more suited to administration in patients. In our previous in vivo studies with b-AP15 we employed a formulation containing 5% Kolliphor EL (previously known as Chremophor EL). Since Kolliphor EL has been described to be associated with the development of hypersensitivity Figure 8) , was recently found to inhibit the deubiquitinase activity of the 19S RP (11) . All of these different DUB inhibitors are electrophiles, and would a priori be expected to confer unspecific reactivity. However, b-AP15, RA-9 and AC17 have been shown not to inhibit total DUB activity in cell lysates (8, 10, 11) . RA-9 was, however, found to inhibit UCHL1, UCHL3 and USP8 in vitro (37) . Furthermore, the chalcone derivatives G5/F6 were reported as more broad specificity DUB inhibitors (38, 39) . We here examined of the ability of VLX1570 to inhibit cellular deubiquitinases using recombinant proteins (performed by Ubiquigent Ltd, Dundee). Remarkably, broad unspecific inhibition of the different DUBs in the panel was not observed. In addition we also found that VLX1570 did not inhibit the non-DUB cysteine protease caspase-3. The basis for these differences in results using various chalcone-and curcumin-analogs is unclear.
Considering the expected cytotoxicity resulting from blocking of proteasome function, we believe it to be likely that the inhibition of proteasomal DUBs (USP14/UCHL5) is of key importance to the biological effects of α,β unsaturated ketone-containing compounds (for a further discussion, see (4)). In order to further examine the potential general reactivity of VLX1570 we performed a screen for inhibition of cellular kinases. VLX1570 is not a general kinase inhibitor by this analysis, showing a median level of inhibition of the panel of ~4% at 10 µM. The most strongly inhibited kinase was Cdk4 which was inhibited to ~80% by 10 µM VLX1570. In spite of the A general cysteine reactivity of b-AP15/VLX1570 may be predicted to lead to substance depletion due to binding to intracellular thiols. The cytotoxicity of other compounds containing α, β-unsaturated carbonyl groups are indeed inhibited by thiolcontaining compounds such as dithiotreitol (DTT) (27, 28). We found that VLX1570
shows a comparatively low reactivity to DTT, further supporting the notion that VLX1570 is not an overtly reactive compound. Electrophiles have been shown to target functional protein systems in a hierarchical manner (42, 43) . High affinity targets are likely to consist of enzymes with catalytic cysteine that have a low pK a due to the close proximity of neighboring residues (such as histidines). The pK a of the thiols of DTT is ~9.2 and GSH ~9.4 (44), explaining their low reactivities. We 
Conclusions
The results presented here show that VLX1570 has a mechanism of action that is indistinguishable from the hit compound b-AP15. b-AP15 was previously shown to be cytotoxic to numerous cancer types as well as to multiple myeloma cells resistant to the 20S proteasome inhibitor bortezomib, suggesting that proteasome DUB inhibitors may have clinical potential (9) . VLX1570 has been granted IND status by the US Food and Drug Administration and is a candidate drug for the treatment of refractory multiple myeloma and will hopefully contribute to the therapeutic arsenal to treat cancer. VLX1570 was injected into Sprague-Dawley rats (5 mg/kg) during 10 minutes.
Plasma was collected after different times and VLX1570 levels were determined by MS. (A) Inhibition of active-site-directed labeling of proteasomal deubiquitinases. Purified 19S proteasomes (5 nM) were pre-treated with DMSO, VLX1570 and b-AP15 (50 µM) for 10 min at room temperature, followed by labeling with HA-UbVS and immunoblotting. (B) Inhibition of Ub-VS labeling of USP14 by VLX1570 in exposed cells. KMS-11 myeloma cells were treated with 1 µM VLX1570 for 6h and 25 µg protein from whole cell lysates were subsequently labeled with Ub-VS (1 µM), followed by SDS gel electrophoresis and immunoblotting with an USP14 antibody. Shown are triplicate samples of cells exposed to solvent or VLX1570. The lower band represents inactive USP14 enzyme. (C) Induction of polyubiquitin conjugates in KMS-11 myeloma cells. Cells were exposed to DMSO, 1µM VLX1570, 100 nM bortezomib, 100 µM IU1, 5 µM WP1130 or 1 µM b-AP15 for 6h and 18h, extracts prepared and subjected to immunoblotting with the indicated antibodies.
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